valu usd unless otherwis note
huge us tavr growth
view ew post huge us tavr ep beat
manag expect ww tavr growth y/i also
manag rais ep guidanc expect hit top-end
revenu guid rais estim price target
world-wide revenu ep came consensu driven
tavr revenu world-wide revenu y/i
growth rbce ou revenu grew eur
jap row non-gaap ep
consensu guidanc vs rbce fce
driven higher revenu lower oper expens actual
vs fce lower effect tax rate actual vs fce
us tavr grew well consensu magnitud
us tavr growth impress driven unexpect
bolu tavr treatment follow ew trial indic
expans low-risk patient segment ww tavr revenu
rbce fce y/i increas critic
revenu rbce fce increas y/i
surgic structur heart revenu rbce vs fce
increas y/i tmtt slight disappoint
gener revenu rbce vs fce
manag expect ww underli tavr growth
previous low doubl digit ew
expect ww sale around top prior rang
tavr compani expect ww revenu around top
prior guidanc manag expect tavr
growth return low doubl digit slower growth tmtt
manag forecast revenu previous
revenu doubl structur heart manag
reiter revenu forecast likewis manag
reiter critic revenu high end
rang due strong beat manag increas adjust
ep guidanc fce final
manag forecast revenu fce
adjust ep fce
rais estim increas price target
model revenu previous
previous respect major revenu
increas due strong outlook tavr move bottom-
line model adjust ep previous
previous revenu adjust
ep respect chang model yield
pt previous support outperform rate
price prior trade day market close estimate unless otherwis note
ew remain attract multi-year growth stori large-
cap med-tech view believ ew deliv
revenu compound-annual-growth-rate next three year
growth rate large-cap compani coverag
manag project ww tavr market
growth driver includ continu
penetr intermediate-risk sever symptomat aortic
stenosi patient expans low-risk popul
onward potenti approv asymptomat
patient basi early-tavr trial improv
patient awar tavr time
manag set view realist revenu
forecast ew project revenu growth
upper end initi guidanc
rang ew project tavr sale previous
guidanc despit competit price
reimburs pressur demonstr underli
strength tavr franchis ew also expect
sale contribut transcathet mitral tricuspid
tmtt pipelin advanc pascal two separ
trial end primari secondari
deliv transsept also enter trial ew
also plan move forward trial pascal
ew forecast tmtt market believ
variou therapi option compani develop
yield least market share impli
annual sale given size market opportun
inher complex treat mitral valv diseas
room multipl compani flourish view
bloomberg capit market estim upside/downside/target
dcf model yield base case price target key
assumpt follow revenu compound-annual-growth-rate
driven double-digit growth tavr/
mitral franchis mid-single-digit growth two
product categori surgic valv critic ebit
margin tax rate
forecast period cash flow dcf
model discount use wacc
upsid scenario valu assum low-double-digit
y/i revenu growth compound-annual-growth-rate driven
expans moder aortic stenosi asymptomat
along meaning revenu contribut
downsid scenario valu assum mid-single-
digit tavr revenu growth due slower adopt among
intermediate-risk low-risk patient stronger competit
slower expect progress
dcf model yield base case price target key assumpt follow
revenu growth compound-annual-growth-rate driven double-digit growth tavr/
mitral franchis mid-single-digit growth two product categori surgic
valv critic ebit margin tax rate
forecast period cash flow dcf model discount use
wacc price target support outperform rate
risk rate price target
risk price target rate includ limit increas competit
market opportun currenc litig reimburs clinic trial risk
edward lifesci global player product technolog design treat
cardiovascular diseas compani focus specif cardiovascular opportun
includ heart valv diseas critic care technolog peripher vascular diseas
